-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $21

Benzinga·02/25/2026 15:06:57
Listen to the news
RBC Capital analyst Lisa Walter maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Sector Perform and lowers the price target from $22 to $21.